Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease?

Novartis Foundation Symposium

Volumn 235, Issue , 2001, Pages 11-25

  Andersen, Julie K ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE; IRON;

ANIMAL; HUMAN; METABOLISM; MOUSE; PARKINSON DISEASE; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; GLUTATHIONE; HUMANS; IRON; MICE; PARKINSON DISEASE;

EID: 0035227581     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (27)

1. Ali SF, David SN, Newport GD, Cadet JL, Slikker W Jr 1994 MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse 18:27-34
2. Andersen JK, Frim DM, Isacson O, Beal MF, Breakefield XO 1994 Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Brain Res 656:108-114
3. Balijepalli S, Boyd MR, Ravindranath V 1999 Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation. Neuropharmacology 38:567-577
4. Bannon MJ, Goedert M, Wolff OH 1984 The possible relationship of glutathione, melanin, and 1-methyl-4-phenyl-1,2,5,6,-tetrahydropyridine (MPTP) to Parkinson's disease. Biochem Pharmacol 33:2697-2698
5. Beal MF 1992 Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 31:119-130
6. Cohen G, Farooqui R, Kesler N 1997 Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad Sci USA 94:4890-4894
7. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P 1995 A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem 65:717-724
8. Dexter DT, Carayon A, Vidailhet M et al 1990 Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 55:16-20
9. Griffith OW 1980 Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 106:207-212
10. Griffiths PD, Dobson BR, Jones GR, Clarke DT 1999 Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryoelectronmicroscopy. Brain 122:667-673
11. Hallman H, Lange J, Olson L, Stromberg I, Jonsson G 1985 Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse. J Neurochem 44:117-127
12. Harrison PM, Arosio P 1996 The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1275:161-203
13. Jain A, Martensson J, Stole E, Auld PA, Meister A 1991 Glutathione deficiency leads to mitochondrial damage in brain. Proc Natl Acad Sci USA 88:1913-1917
14. Jellinger KA 1999 The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14:115-140
15. Jellinger KA, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MB 1990 Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect 2:327-340
16. Jenner P, Olanow CW 1998 Understanding cell death in Parkinson's disease. Ann Neurol (suppl) 44:S72-S84
17. Kienzl E, Puchinger L, Jellinger K, Linert W, Stachelberger H, Jameson RF 1995 The role of transition metals in the pathogenesis of Parkinson's disease. J Neurol Sci (suppl) 134:69-78
18. Klivenyi P, Andreassen OA, Ferrante RJ et al 2000 Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J Neurosci 20:1-7
19. Koeppen AH 1995 The history of iron in the brain. J Neurol Sci (suppl) 134:1-9
20. Mann VM, Cooper JM, Daniel SE et al 1994 Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 36:876-881
21. Perry TL, Yong VW 1986 Idiopathic Parkinson's disease, progressive supranuclear palsy, and glutathione metabolism in the substantia nigra in Parkinson's disease. Neurosci Lett 67: 305-310
22. Perry TL, Godin DV, Hansen S 1982 Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33:305-310
23. Riederer P, Sofic E, Rausch WD et al 1989 Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52:515-520
24. Sian J, Dexter DT, Lees AJ et al 1994 Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348-355
25. Tetrud JW, Langston JW 1989 MPTP-induced parkinsonism as a model for Parkinson's disease. Acta Neurol Scand Suppl 126:35-40
26. Thomas CE, Aust SD 1986 Reductive release of iron from ferritin by cation free radicals of paraquat and other bipyridyls. J Biol Chem 261:13064-13070
27. Youdim MB, Ben-Shacher D, Reiderer P 1993 The possible role of iron in the etiopathology of Parkinson's disease. Mov Disorders 8:1-12